- Email: [email protected]
Chemotherapy-induced amenorrhea: Prognostic impact on premenopausal Egyptian patients with breast cancer
abstracts
Annals of Oncology
Chemotherapy-induced amenorrhea: Prognostic impact on premenopausal Egyptian patients with breast cancer
K. Abdel Karim, D.A.G. Abdel Al, C. Reda, H. Nohran Clinical Oncology, Ain Shams University Faculty of Medicine, Cairo, Egypt Background: Breast cancer is the second most frequent cancer among women. Disease free survival (DFS) and overall survival (OS) have been improved by different adjuvant chemotherapy regimens; as a consequence, premenopausal patients developed chemotherapy-induced amenorrhea (CIA). Although chemotherapy and ovarian ablation independently improve the outcome of breast cancer, there is controversy about the effect of CIA in these patients. The aim of this study was to analyze the prognostic impact of chemotherapy- induced amenorrhea (CIA) on disease-free survival and overall survival in premenopausal patients with breast cancer following adjuvant chemotherapy. Methods: Retrospectively, we reviewed the data of 200 premenopausal breast cancer patients, who underwent adjuvant chemotherapy at the Clinical Oncology Department of Ain Shams University, Cairo, Egypt during 2014. The data of one hundred ninetytwo patients were analyzed in the study. CIA was defined as the absence of menstruation for a year after the end of chemotherapy. The survival analyses were done using the Kaplan-Meier method and the log Rank Test. Results: The median follow-up was 4 years. Mean age was 40.8 6 6 years. CIA occurred in 66.1% of patients. Age and tumor grade were CIA predictors in logistic regression analysis. The 4-year disease-free survival (DFS) was higher in the CIA group than that in the non-CIA group (47.39 months vs 31.80 months, respectively; P ¼ < 0.001), and the 4- year overall survival (OS) was higher in the CIA group than that of the non-CIA group (47.85 months vs 45.296 months, respectively; P ¼ 0.030). Conclusions: Chemotherapy-induced amenorrhea positively affects disease-free survival and overall survival in the Egyptian premenopausal breast cancer patients treated with adjuvant chemotherapy. It was a better prognostic marker and might be used as a surrogate marker for effective chemotherapy in those patients. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
v90 | Breast Cancer, Early Stage
Volume 30 | Supplement 5 | October 2019
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_5/mdz240.091/5576470 by guest on 26 October 2019
267P
Annals of Oncology
Chemotherapy-induced amenorrhea: Prognostic impact on premenopausal Egyptian patients with breast cancer
K. Abdel Karim, D.A.G. Abdel Al, C. Reda, H. Nohran Clinical Oncology, Ain Shams University Faculty of Medicine, Cairo, Egypt Background: Breast cancer is the second most frequent cancer among women. Disease free survival (DFS) and overall survival (OS) have been improved by different adjuvant chemotherapy regimens; as a consequence, premenopausal patients developed chemotherapy-induced amenorrhea (CIA). Although chemotherapy and ovarian ablation independently improve the outcome of breast cancer, there is controversy about the effect of CIA in these patients. The aim of this study was to analyze the prognostic impact of chemotherapy- induced amenorrhea (CIA) on disease-free survival and overall survival in premenopausal patients with breast cancer following adjuvant chemotherapy. Methods: Retrospectively, we reviewed the data of 200 premenopausal breast cancer patients, who underwent adjuvant chemotherapy at the Clinical Oncology Department of Ain Shams University, Cairo, Egypt during 2014. The data of one hundred ninetytwo patients were analyzed in the study. CIA was defined as the absence of menstruation for a year after the end of chemotherapy. The survival analyses were done using the Kaplan-Meier method and the log Rank Test. Results: The median follow-up was 4 years. Mean age was 40.8 6 6 years. CIA occurred in 66.1% of patients. Age and tumor grade were CIA predictors in logistic regression analysis. The 4-year disease-free survival (DFS) was higher in the CIA group than that in the non-CIA group (47.39 months vs 31.80 months, respectively; P ¼ < 0.001), and the 4- year overall survival (OS) was higher in the CIA group than that of the non-CIA group (47.85 months vs 45.296 months, respectively; P ¼ 0.030). Conclusions: Chemotherapy-induced amenorrhea positively affects disease-free survival and overall survival in the Egyptian premenopausal breast cancer patients treated with adjuvant chemotherapy. It was a better prognostic marker and might be used as a surrogate marker for effective chemotherapy in those patients. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
v90 | Breast Cancer, Early Stage
Volume 30 | Supplement 5 | October 2019
Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_5/mdz240.091/5576470 by guest on 26 October 2019
267P